| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/02/2002 | EP1165556A1 Derivatives of pyrimido[6,1-a]isoquinolin-4-one |
| 01/02/2002 | EP1165555A2 Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands |
| 01/02/2002 | EP1165554A1 New endothelin converting enzyme inhibitors, their production and their use |
| 01/02/2002 | EP1165553A1 C10 ester substituted taxanes as antitumor agents |
| 01/02/2002 | EP1165552A1 C7 carbonate substituted taxanes as antitumor agents |
| 01/02/2002 | EP1165551A1 C10 carbamoyloxy substituted taxanes as antitumor agents |
| 01/02/2002 | EP1165550A1 C10 carbonate substituted taxanes as antitumor agents |
| 01/02/2002 | EP1165549A1 C7 carbamoyloxy substituted taxanes as antitumor agents |
| 01/02/2002 | EP1165548A1 Novel method for producing doxazosin mesylate in a crystalline modification designated as form a |
| 01/02/2002 | EP1165545A1 Novel compounds |
| 01/02/2002 | EP1165544A1 Substituted 1,4-dihydroindeno[1,2-c]pyrazoles as inhibitors of tyrosine kinase |
| 01/02/2002 | EP1165543A1 PROCESS FOR PREPARING S-(R*,S*)] -$g(b) - 1- 1-OXO-3- (4-PIPERIDINYL) PROPYL] -3-PIPERIDINYL] CARBONYL] AMINO] -3- PYRIDINEPROPANOIC ACID AND DERIVATIVES |
| 01/02/2002 | EP1165542A1 4-substituted quinoline derivatives as nk-3 and/or gaba(a) receptor ligands |
| 01/02/2002 | EP1165541A1 Dimeric compounds and as inhibitors of neuraminidase |
| 01/02/2002 | EP1165540A1 Tetrahydropyran derivatives and their use as therapeutic agents |
| 01/02/2002 | EP1165537A1 Hydroxymatairesinol in cancer prevention |
| 01/02/2002 | EP1165534A2 Benzoylguanidine derivatives with advantageous properties, method for producing them and their use in the production of medicaments |
| 01/02/2002 | EP1165533A2 Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
| 01/02/2002 | EP1165532A1 Antibacterial agents |
| 01/02/2002 | EP1165528A1 Novel morpholine derivatives, method for the production thereof and pharmaceutical preparations containing said derivatives |
| 01/02/2002 | EP1165527A1 Pesticidal enantiomer-pure 2,4-disubstituted oxazolines |
| 01/02/2002 | EP1165523A1 Neurotrophic substituted pyrimidines |
| 01/02/2002 | EP1165521A1 FUSED PYRIDOPYRIDAZINE INHIBITORS OF cGMP PHOSPHODIESTERASE |
| 01/02/2002 | EP1165519A1 Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics |
| 01/02/2002 | EP1165518A2 Benzimidazole and imidazolopyridine derivatives, their preparation and their use as selective modulators of bradykinin b2 (= bk-2) receptors |
| 01/02/2002 | EP1165517A1 N-benzimidazolylmethyl- and n-indolylmethyl-benzamides and their use as crf modulators |
| 01/02/2002 | EP1165516A2 Heterocyclic urea and related compounds useful as anti-inflammatory agents |
| 01/02/2002 | EP1165514A1 3-(anilinomethylene) oxindoles as protein tyrosine kinase and protein serine/threonine kinase inhibitors |
| 01/02/2002 | EP1165513A1 Indolinone compounds as kinase inhibitors |
| 01/02/2002 | EP1165510A1 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of cns disorders |
| 01/02/2002 | EP1165508A1 Anticancer calcium channel blockers |
| 01/02/2002 | EP1165506A1 Substituted azetidin-2-ones as cysteine protease inhibitors |
| 01/02/2002 | EP1165505A1 Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
| 01/02/2002 | EP1165504A2 INHIBITORS OF LFA-1 BINDING TO ICAMs AND USES THEREOF |
| 01/02/2002 | EP1165502A1 Diaryl derivatives and their use as medicaments |
| 01/02/2002 | EP1165501A1 Alkenyl- and alkynyl-containing metalloprotease inhibitors |
| 01/02/2002 | EP1165500A1 Amide derivatives as inhibitors of matrix metalloproteinases,tnf-alpha,and aggrecanase |
| 01/02/2002 | EP1165495A1 Resorcinol derivatives |
| 01/02/2002 | EP1165494A2 Hsv primase inhibitors |
| 01/02/2002 | EP1165493A1 Nitrogen mustard compounds and prodrugs therefor |
| 01/02/2002 | EP1165491A1 Lta4 hydrolase inhibitors |
| 01/02/2002 | EP1165490A1 Substituted 2-aminobenzamide caspase inhibitors and the use thereof |
| 01/02/2002 | EP1165487A1 Derivatives of venlafaxine and methods of preparing and using the same |
| 01/02/2002 | EP1165472A1 Methods for the preparation of biphenyl isoxazole sulfonamides |
| 01/02/2002 | EP1165185A2 Human tumor necrosis factor receptor-like 2 |
| 01/02/2002 | EP1165184A2 Estrogen receptor-beta antagonism and bone diseases |
| 01/02/2002 | EP1165183A1 Low dose estrogen interrupted hormone replacement therapy |
| 01/02/2002 | EP1165143A2 Method for expressing proteins |
| 01/02/2002 | EP1165141A2 Novel formulations comprising lipid-regulating agents |
| 01/02/2002 | EP1165139A2 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinasese inhibitor |
| 01/02/2002 | EP1165138A1 Method for a programmed controlled ovarian stimulation protocol |
| 01/02/2002 | EP1165137A1 Sphingomyelin containing preparation for the enhancement of tumor therapy |
| 01/02/2002 | EP1165136A1 Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease |
| 01/02/2002 | EP1165134A1 Use of anti-ferritin monoclonal antibodies in the treatment of some cancers |
| 01/02/2002 | EP1165124A1 Recombinant neospora antigens and their uses |
| 01/02/2002 | EP1165113A2 USE OF ErbB RECEPTOR LIGANDS IN TREATING DIABETES |
| 01/02/2002 | EP1165110A2 Antagonists of hmg1 for treating inflammatory conditions |
| 01/02/2002 | EP1165108A1 Use of a serenoa repens extract for the production of a medicament to treat prostate cancer |
| 01/02/2002 | EP1165106A2 Composition and method for inducing apoptosis in prostate cancer cells |
| 01/02/2002 | EP1165099A2 Methods for limiting scar and adhesion formation |
| 01/02/2002 | EP1165098A2 Peroxovanadium compounds as antineoplastic agents for the treatment of cancer |
| 01/02/2002 | EP1165097A2 A pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same |
| 01/02/2002 | EP1165096A2 Use of cytidine derivatives for the treatment of leukaemia |
| 01/02/2002 | EP1165095A1 Agents for intravitreal administration to treat or prevent disorders of the eye |
| 01/02/2002 | EP1165094A1 Dispersible macrolide compounds and method for the production thereof |
| 01/02/2002 | EP1165092A1 Cyclopentanone derivatives and their use |
| 01/02/2002 | EP1165091A1 Pharmaceutical emulsions for retroviral protease inhibitors |
| 01/02/2002 | EP1165090A2 A method of treating bulimia nervosa and related eating disorders by administration of atypical antipsychotic medications |
| 01/02/2002 | EP1165089A1 Use of tianeptin in the production of medicaments to treat neurodegenerative pathologies |
| 01/02/2002 | EP1165088A1 Use of vasopeptidase inhibitors to treat angina pectoris |
| 01/02/2002 | EP1165087A1 In vivo stain compounds and methods of use to identify dysplastic tissue |
| 01/02/2002 | EP1165086A2 Bupropion metabolites and methods of their synthesis and use |
| 01/02/2002 | EP1165085A1 Phthalazine derivatives for treating inflammatory diseases |
| 01/02/2002 | EP1165083A2 Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites |
| 01/02/2002 | EP1165082A1 Inhibitors of prenyl-protein transferase |
| 01/02/2002 | EP1165081A1 Tolperison-containing, pharmaceutical preparation for oral administration |
| 01/02/2002 | EP1165080A2 Use of substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections |
| 01/02/2002 | EP1165079A2 Improved dialysis solutions and methods |
| 01/02/2002 | EP1165078A1 Methods of inducing cancer cell death and tumor regression |
| 01/02/2002 | EP1165077A2 Viral treatment |
| 01/02/2002 | EP1165076A1 6-azaindole compounds as antagonists of gonadotropin releasing hormone |
| 01/02/2002 | EP1165074A2 Viral treatment |
| 01/02/2002 | EP1165073A1 Combination of antibiotic and nucleic acid binding compound for bacterial antibiotic resistance |
| 01/02/2002 | EP1165072A2 Valdecoxib compositions |
| 01/02/2002 | EP1165071A2 Improved cancer treatment with temozolomide |
| 01/02/2002 | EP1165070A1 Thiadiazolyl urea or thiourea derivatitives for antiviral treatment |
| 01/02/2002 | EP1165069A1 Antitumour synergistic composition |
| 01/02/2002 | EP1165068A1 C10 heterosubstituted acetate taxanes as antitumor agents |
| 01/02/2002 | EP1165067A1 A process for the preparation of aziridinyl epothilones from oxiranyl epothilones |
| 01/02/2002 | EP1165066A1 Use of lipoxin compounds for inhibiting of tnf-(alfa) initiated neutrophil response |
| 01/02/2002 | EP1165065A1 Swallowable tablets with high content of n-acetylcysteine |
| 01/02/2002 | EP1165064A2 Novel inhibitors of formation of advanced glycation endproducts (age's) |
| 01/02/2002 | EP1165063A1 Use of succinic acid or salts thereof for the treatment of diabetes mellitus and wound healing |
| 01/02/2002 | EP1165062A1 Use of vitamin c or analogues for promoting transformation of inactive procollagen into active collagen |
| 01/02/2002 | EP1165061A2 Compound preparation made of vitamin d metabolites or vitamin d analogues and an oestrogenic component for treating osteoporosis |
| 01/02/2002 | EP1165060A1 Treatment of gallstones |
| 01/02/2002 | EP1165058A2 Use of azalide antibiotics for the topical treatment or prevention of ocular infections |
| 01/02/2002 | EP1165057A2 Endodontic fibers and methods of use therefor |
| 01/02/2002 | EP1165055A2 Pharmaceutical composition containing an extrusion additive |
| 01/02/2002 | EP1165054A1 Pharmaceutical dosage form for pulsatile delivery of methylphenidate |